Law360, New York ( November 8, 2013, 12:50 PM EST) -- According to the U.S. Food and Drug Administration, already more than 100 approved drugs contain information on genomic biomarkers, highlighting that personalized medicine is no longer a future fantasy, but it is present reality. Recent successes of co-development of personalized medicine including a drug and a companion diagnostic include Vemurafenib/BRAF V600E, approved in 2011 in 3.6 months through an expedited process; Crizotinib/ALK testing, approved in 2011 in 4.9 months with only 255 patients; and Tefinlar/Melkinist/THxID BRAF test approved in 2013....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.